Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160497 | 0.83 | LMNA (0.55) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL17472299 | 0.82 | HPGD (0.49) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL5098107 | 0.82 | HPGD (0.49) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL5098101 | 0.82 | HPGD (0.49) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL3595574 | 0.81 | CA12 (0.49) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL3595577 | 0.81 | CA12 (0.49) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL1004764 | 0.80 | GAA (0.53) | LMNAALDH1A1RAB9AKDM4EKMT2A | |
| SCHEMBL20594680 | 0.79 | HIF1A (0.36) | SMN1; SMN2LMNAALDH1A1KDM4EGLA | |
| SCHEMBL402047 | 0.78 | LMNA (0.51) | SMN1; SMN2LMNAALDH1A1HPGDRAB9A | |
| SCHEMBL2705192 | 0.78 | MMP2 (0.60) | SMN1; SMN2LMNAALDH1A1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260049192-A1 | DYED ARTICLES FOR VISIBLE AND INFRARED LIGHT ABSORPTION | OAKLEY, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260049217-A1 | DYED ARTICLES FOR VISIBLE LIGHT FILTERING | OAKLEY, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4562000-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119630652-A | Amino heteroaryl kinase inhibitors | 安锐生物医药公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-115335378-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-0323841-B1 | SUBSTITUTED PYRROLE, PYRAZOLE AND TRIAZOLE ANGIOTENSIN II ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-08-04 | — | — | EP | disclosed |
| US-5189048-A | Hypotensive agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-02-23 | — | — | US | disclosed |
| US-5093346-A | Hypotensive agents, congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-03-03 | — | — | US | disclosed |
| US-5081127-A | Hypotensive agents and treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| US-5043349-A | Hypotensive agents, treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-27 | — | — | US | disclosed |
| US-5015651-A | Triazole derivatives for treatment of congestive heart failure | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0323841-A2 | Substituted pyrrole, pyrazole and triazole angiotensin II antagonists | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-07-12 | — | — | EP | disclosed |
| EP-0219706-B1 | N,N-DIALKYLAMINOALKYL-HEXAHYDRO-5-OXO-1H-PYRROLIZINE-3-CARBOXAMIDES | WARNER-LAMBERT COMPANY (US) | 1989-06-21 | — | — | EP | disclosed |
| EP-0219706-A1 | N,N-dialkylaminoalkyl-hexahydro-5-oxo-1H-pyrrolizine-3-carboxamides | WARNER-LAMBERT COMPANY (US) | 1987-04-29 | — | — | EP | disclosed |
| US-4638006-A | Amnesia reversal with N,N-dialkylaminoalkyl-hexahydro-5-oxo 1H-pyrrolizine-3-carboxamides | WARNER LAMBERT COMPANY (US) | 1987-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | SMN1; SMN2 2361/4885LMNA 4245/4885ALDH1A1 1000/4885 |
| US-20260049217-A1 | DYED ARTICLES FOR VISIBLE LIGHT FILTERING | LBR, CRY2, CORO1C | SMN1; SMN2 4367/4885LMNA 24/4885ALDH1A1 845/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | SMN1; SMN2 1998/4885LMNA 3592/4885ALDH1A1 908/4885 |
| US-20260049192-A1 | DYED ARTICLES FOR VISIBLE AND INFRARED LIGHT ABSORPTION | CRY1, CRY2, CLIC1 | SMN1; SMN2 4823/4885LMNA 1257/4885ALDH1A1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.